Search results for " CVC"
showing 3 items of 3 documents
One shoot seldinger central venous catheterization in dialyzed patients
2015
Introduction: Central Venous Catheterization is necessary in uremic patient (before dialysis) and many other conditions. In this study we demonstrated the advantages of ultrasonography to perform the procedure. Materials and methods: 48 uremic patient were submitted to ultrasound-guided central venous catheterization. The procedure was performed following the Seldinger “one shot” technique. Results: The mean operative time was 4 minutes, with a high rate of success (100%) and a low percentage of complications (2%). Conclusion: The ultrasound-guided central venous catheterization is a safe procedure, rapid and easy to perform. The procedure has a low rate of failures and complications and a …
Vantaggi degli ultrasuoni nel posizionamento di un agocannula nella vena giugulare interna (nuove note di tecnica)
2004
The authors analized the result of 175 central venous ca he- terization CVC. of internal jugular vein performed with the ultrasound guide (US) from January 1998 to October 2002. The average performing time was 45 minutes. 98.2% of success and 4% of complications (one pagal hypotension, one artery puncture, four catheter dislocation, one haeiuatoinai). The US guide CVC is a safe procedure with short performing time, low rate of failures and complications and high rate of success: it is helpful in all patients with vascular anatomical variations, with not visualized or Land marks and with coagulation disorders.
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
2018
The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score [NAS] ≥4, and liver fibrosis (stages 1-3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome was ≥2-point improvement in NAS and no worsening of fibrosis at year 1. Key secondary outcomes were: resolution of steatohepatitis and no worsening of fibrosis; improvement in fibrosis by ≥1 stag…